KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Change in Account Payables (2016 - 2025)

TherapeuticsMD's Change in Account Payables history spans 16 years, with the latest figure at $114000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 375.0% year-over-year to $114000.0; the TTM value through Dec 2025 reached $119000.0, down 48.48%, while the annual FY2025 figure was $119000.0, 48.48% down from the prior year.
  • Change in Account Payables reached $114000.0 in Q4 2025 per TXMD's latest filing, up from -$87000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $5.0 million in Q3 2021 to a low of -$10.8 million in Q1 2021.
  • Average Change in Account Payables over 5 years is -$202900.0, with a median of $14000.0 recorded in 2024.
  • Peak YoY movement for Change in Account Payables: plummeted 946.84% in 2023, then skyrocketed 4250.0% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $414000.0 in 2021, then plummeted by 80.92% to $79000.0 in 2022, then tumbled by 946.84% to -$669000.0 in 2023, then soared by 103.59% to $24000.0 in 2024, then skyrocketed by 375.0% to $114000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Change in Account Payables are $114000.0 (Q4 2025), -$87000.0 (Q3 2025), and $174000.0 (Q2 2025).